These findings indicate that genetically-determined elevated plasma sIL6R level reduces systemic inflammation and decreases the risk of RA, a disease genetically-correlated to different CVDs (stroke, rg = 0.19, P = 0.003; AF, rg = 0.08, P = 0.01) and with a strong immune component. This evidence concerns the gene IL6R and atrial fibrillation.